ACE2 and COVID-19: When we further analyzed ACE2 and CD16 surface expression in the CD14+ monocytes by our gating strategy, we indeed found co-expression of ACE2 and CD16 in CD14+ monocytes at a variety of levels from healthy control and COVID-19 patients (Supplementary Fig. S15a, b).